The Brazilian Registry on Sjögren's Disease (BRAS) is a prospective, national cohort registry. To date, 16 centers from all Brazilian regions are engaged in collaborative research, with the potential for additional centers to be included over time. The BRAS project started in 2021 and has the support of the Brazilian Society of Rheumatology (SBR). The primary objective of BRAS is to generate a set of Brazilian epidemiological data on patients with SjD who meet the 2002 AECG and/or 2016 ACR-EULAR classification criteria, and to promote high-quality clinical research. The Research Electronic Data Capture (REDCap) platform is being used for the entry of clinical data. In addition to demographic and laboratory data, clinical data are being collected, including disease activity (EULAR Sjögren's Syndrome Disease Activity Index - ESSDAI), disease damage (Sjögren's Syndrome Disease Damage Index-SSDDI), comorbidities, cardiovascular risk (Framingham), labial salivary gland biopsy, salivary gland ultrasound, and pharmacological and non-pharmacological treatment. Additionally, patient-reported outcome measures (PROMs) are being incorporated, including the EULAR Sjögren's Syndrome Patient-Reported Index (ESSPRI), Profile of Fatigue and Discomfort (PROFAD), Hospital Anxiety and Depression Scale (HADS), Epworth sleepiness scale (ESE), International Physical Activity Questionnaire-short form (IPAQ-SF), and EuroQol-5 Domain (EQ-5D). The study is currently enrolling 1,010 patients. The mean age of the 1,010 SjD patients is 55.6 ± 13.6 years, with 96.5% of women. Ninety-three percent of patients present with xerostomia, 93.7% xerophthalmia, 78.9% anti-Ro/SSA, and 41.8% anti-La/SSB. Ninety-four percent and 90% of patients have met the 2002 AECG and 2016 ACR-EULAR classification criteria, respectively. There is a potential for future studies to investigate the clinical and laboratory profile, predictors of systemic involvement and cardiovascular risk; prevalence of anxiety and depression and associations, level of physical activity and associations, comorbidities and polypharmacy; in addition, treatment response, follow-up of disease activity and mortality. The next step is to create a biorepository for biological specimens.